Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies. Longboard is also evaluating LP659, a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, in development for the potential treatment of multiple neurological diseases, and LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist, in development for the potential treatment of central nervous system (CNS) diseases and disorders.

	Dec '20	Dec '21	Dec '22	Dec '23
net income	-14.40M -	-27.80M 93.03%	-43.95M 58.09%	-54.42M 23.84%
depreciation and amortization		1K -	5K 400%	5K 0%
deferred income tax
stock based compensation	8.51M -	1.97M 76.88%	2.66M 35.08%	3.25M 22.47%
change in working capital	2.45M -	967K 60.53%	3.12M 222.54%	1.27M 59.38%
accounts receivables
inventory
accounts payables	1.21M -	-185K 115.25%	282K 252.43%	-308K 209.22%
other working capital	1.24M -	1.15M 6.87%	2.84M 146.27%	1.57M 44.48%
other non cash items		157K -	101K 35.67%	-972K 1,062.38%
net cash provided by operating activities	-3.44M -	-24.70M 617.75%	-38.06M 54.07%	-50.87M 33.64%
investments in property plant and equipment		-16K -
acquisitions net
purchases of investments		-40.70M -	-57.61M 41.56%	-71.72M 24.48%
sales maturities of investments			40.55M -	95.95M 136.62%
other investing activites
net cash used for investing activites		-40.72M -	-17.06M 58.09%	24.23M 242.01%
debt repayment
common stock issued	55.56M -	84.77M 52.59%		31.79M -
common stock repurchased	-205K -	-1K 99.51%
dividends paid
other financing activites	3.40M -	-8.32M 344.41%	-444K 94.66%	-1.60M 259.46%
net cash used provided by financing activities	58.76M -	76.45M 30.11%	-444K 100.58%	30.19M 6,899.77%
effect of forex changes on cash
net change in cash	55.32M -	11.03M 80.06%	-55.57M 603.82%	3.56M 106.40%
cash at beginning of period		55.32M -	66.35M 19.94%	10.78M 83.76%
cash at end of period	55.32M -	66.35M 19.94%	10.78M 83.76%	14.33M 33.00%
operating cash flow	-3.44M -	-24.70M 617.75%	-38.06M 54.07%	-50.87M 33.64%
capital expenditure		-16K -
free cash flow	-3.44M -	-24.72M 618.22%	-38.06M 53.97%	-50.87M 33.64%

COM:LONGBOARDPHARMA

Longboard Pharmaceuticals

Last Close

59.77

22/11 21:00

Market Cap

1.44B

Beta: -

Volume Today

1.29M

Avg: -

Preview